Combination Antiretroviral Therapy Is Associated With Reduction in Liver Fibrosis Scores in HIV-1 Infected Subjects

Yijia Li, MD, Jing Xie, PhD, Yang Han, PhD, Huanling Wang, MD, Wei Lv, MD, Fuping Guo, MD, Zhifeng Qiu, PhD, Yanling Li, BS, Shanshan Du, BS, Xiaojing Song, BS, Ting Zhu, BS, Chloe L. Thio, MD and Taisheng Li, MD, PhD

Abstract: HIV increases the risk of liver disease as do two common coinfections, hepatitis B and C viruses (HBV and HCV). However, whether combination antiretroviral therapy (cART) reverses or exacerbates hepatic fibrosis remains unclear.

This was an observational retrospective study. cART-naive HIV-infected subjects without a history of substance abuse (including alcohol) had liver disease stage determined by aspartate aminotransferase-to-platelet ratio indices (APRIs) and fibrosis-4 (FIB-4) before and 24 and 48 weeks after cART. All the data were retrieved from previously established cohorts. Values before and after cART were compared using Wilcoxon test for paired samples. Regression analyses were used to determine factors associated with moderate-to-severe liver disease.

Of the 1105 HIV-infected subjects, 120 were HBV coinfected and 64 were HCV coinfected. About 20% of HIV monoinfected participants had APRI and FIB-4 scores consistent with moderate-to-significant fibrosis compared to ~36% of HIV–HBV coinfected and 67% to 77% of HIV–HCV coinfected participants. In adjusted analyses compared with HIV monoinfection, HCV coinfection was associated with 1.12-fold higher APRI (P < 0.001) and a 1.12-fold higher FIB-4 (P = 0.007) prior to cART; while HCV coinfecion was associated with 1.94-fold higher APRI (P < 0.001) and a 1.43-fold higher FIB-4 (P < 0.001). After 48 weeks of cART, both fibrosis scores decreased in all subjects; however, HCV coinfecion was still associated with higher fibrosis scores at week 48 compared to HIV monoinfection.

cART was associated with improvement in hepatic fibrosis scores in the majority of HIV-hepatitis coinfected and HIV-monoinfected Chinese participants.

(Medicine 95(5):e2660)

INTRODUCTION

After the introduction of combination antiretroviral therapy (cART), morbidity and mortality rates have decreased dramatically in people living with HIV; however, non-AIDS defining diseases are now the leading causes of death with liver-related deaths one of the most common.1-3 Given that hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) have overlapping routes of transmission, viral hepatitis and HIV coinfection is common and accounts for the majority of liver disease in subjects with HIV.3 It is well established that in HIV/viral hepatitis coinfecion, HIV accelerates the progression of viral hepatitis and its related liver disease, including liver fibrosis, cirrhosis, and hepatocellular carcinoma.3,7 However, there are limited data on the prevalence of fibrosis in HIV-infected subjects both with and without viral hepatitis.

A recent study by Price et al suggests that HIV infection per se is associated with increased aspartate aminotransferase (AST)-to-platelet (PLT) ratio index (APRI), a surrogate marker for hepatic fibrosis. However, this article does not further distinguish the fibrogenic effects of HBV and HCV coinfection and does not demonstrate whether cART reverses the fibrogenic effect of HIV infection.8 Other studies focus on the effect of cART on the regression of hepatic fibrosis in HIV/HCV coinfection, but the results are discordant.9,10 In HIV/HBV coinfected population, one French study found that long-term tenofovir use was associated with a decrease in fibrosis scores11; however, that study did not have HIV monoinfected subjects as a comparison group. There are no data regarding fibrosis prevalence and cART response in HIV-infected subjects from Asia.
For the evaluation of hepatic fibrosis in large populations, liver biopsy, the gold standard, is not feasible due to its cost, invasiveness, and complications. APRI and fibrosis-4 (FIB-4), two noninvasive markers for hepatic fibrosis, have been validated in HBV- and HCV-infected populations. They have also been used to evaluate hepatic fibrosis in HIV/HBV or HIV/HCV coinfected populations and are reported to have moderate concordance. In addition, they are closely associated with morbidity and mortality in HIV and viral hepatitis coinfected population.

In this study, we used four large multicenter cohorts of HIV-infected Chinese subjects including HIV monoinfected, HIV–HBV coinfected, and HIV–HCV coinfected to evaluate the prevalence and risk factors for hepatic fibrosis, as measured by APRI and FIB-4, prior to cART. We also evaluated the impact of cART on these hepatic fibrosis measurements.

SUBJECTS AND METHODS

Study Population

Subjects in this study came from one the following four HIV cohorts in China: 10th 5-year (10-5) cohort (recruited between 2005 and 2007, previously reported in, n = 148), 11th 5-year (11-5) cohort (recruited between 2008 and 2010, previously reported in, n = 484), 12th 5-year (12-5) cohort (recruited between 2012 and 2014, n = 402), and outpatient clinics (OP, recruited between 2012 and 2014, only from Peking Union Medical College Hospital, n = 71). The clinical centers in Northeastern, Northwestern, and Southeastern China are located in urban areas and are tertiary/specialized hospitals; while District CDC in Nanning, Longtan Hospital in Nanning, Nanning Forth People’s Hospital, Yunnan AIDS Care Center, Kunming Third People’s Hospital, and Honghe First People’s Hospital are all tertiary/specialized hospitals located in less-developed areas in Southwestern China. This research was approved by Institutional Review Board of Peking Union Medical College Hospital and was in compliance with relevant local laws and the ethical requirements of the Declaration of Helsinki. Informed consent was obtained from every patient. Inclusion criteria for these parent cohorts were determined by local laws and the ethical requirements of the Declaration of Helsinki. Informed consent was obtained from every patient. Inclusion criteria for these parent cohorts were determined by local laws and the ethical requirements of the Declaration of Helsinki. Informed consent was obtained from every patient.

Inclusion criteria for these parent cohorts were determined by the individual studies, including CD4 cells lower than 350 cells/μL in 10th 5-year cohort and 11th 5-year cohort, CD4 cells lower than 500 cells/μL in 12th 5-year cohort and outpatient clinics; cART-naïve; no intravenous drug use; no heavy alcohol use (defined as more than 40 g/d for male and 20 g/d for female or drinking that prevents the patient from taking the medications regularly, based on self-report); alanine transaminase (ALT) and AST lower than 140 IU/L and platelet count (PLT) higher than 40,000 per μL. In this study, we only included subjects with baseline HBV serology and HCV RNA profiles available. For those with positive anti-HCV antibody but negative HCV RNA, we considered them as HIV monoinfected. Subjects visited local medical centers for anti-HCV antibody but negative HCV RNA, we considered them as HIV monoinfected. Subjects visited local medical centers for HIV monoinfected, HIV–HBV coinfected, and HIV–HCV coinfected to evaluate the prevalence and risk factors for hepatic fibrosis, as measured by APRI and FIB-4, prior to cART. We also evaluated the impact of cART on these hepatic fibrosis measurements.

Clinical and Laboratory Data

At each visit, HIV RNA (COBAS Ampliprep/TaqMan48 real-time RT-PCR, Roche Diagnostics, Indianapolis, IN), CD4 cell count (flow cytometry, Beckman-Coulter, Brea, CA), ALT, AST, and platelets were measured. The upper limit of normal (ULN) for ALT and AST was 40 IU/L. HBsAg and anti-HCV were determined by Architecture i2000SR platform (Abbott Diagnostics, Abbott Park, IL) and HCV RNA was determined by COBAS Ampliprep/TaqMan48 real-time RT-PCR (Roche Diagnostics) at the baseline visit. All baseline tests were obtained within 2 weeks prior to cART initiation.

APRI was defined as (AST/ULN)/PLT × 100, and an APRI > 0.5 was considered as moderate-to-significant hepatic fibrosis. FIB-4 was defined as (AST × Age)/(PLT × square root of ALT), and FIB-4 > 1.45 was considered as moderate-to-significant fibrosis. The unit for platelets in both definitions is 10⁹/L. These APRI and FIB-4 cut-offs have been shown in meta-analyses to have moderate diagnostic accuracy for significant or greater liver disease.

Statistical Analysis

Noncategorical variables were analyzed by using Kruskal–Wallis test and were summarized with median and interquartile ranges (IQRs). Categorical variables were analyzed by Chi-squared test or Fisher exact test. Risk factors for having moderate-to-significant hepatic fibrosis at baseline were determined by both logistic regression and linear regression. In logistic regression, APRI and FIB-4 scores were treated as categorical scores with cut-off values of 0.50 and 1.45, respectively. Since distributions of both scores were right-skewed, the scores were natural log-transformed (Ln); coefficients of all risk factors in linear regression were reported as fold changes (previously described in the study by Price et al). To compare fibrosis scores at weeks 24 and 48 with baseline levels, Wilcoxon test for paired samples was used. In order to evaluate factors associated with significant fibrosis at week 48, we conducted multivariate linear regressions and included all subjects with data available at week 48. In this analysis, CD4 cell count change was calculated as CD4 cell count at week 48 minus CD4 cell count at baseline and then divided into 4 quartiles. For all tests except Wilcoxon tests for paired samples, P < 0.05 was considered to be statistically significant. For Wilcoxon tests for paired samples, P < 0.025 was considered to be statistically significant according to Bonferroni correction. In multivariate regressions, factors with P < 0.15 in univariate models were included, and age, sex, routes of transmission, and cohorts were adjusted for in all cases. Stata 13 (StataCorp, College Station, TX) was used for all analyses.

RESULTS

Baseline Characteristics

This study included 1105 HIV-infected subjects of whom 120 (10.9%) were HIV–HBV coinfected and 64 (5.8%) were HIV–HCV coinfected. Most of the subjects were 30 to 40 years old, male, and infected via sexual transmission.
TABLE 1. Baseline Characteristics

| Total (n = 1105) | HIV Monoinfection (n = 921) | HIV–HBV Coinfection (n = 120) | HIV–HCV Coinfection (n = 64) | P |
|-----------------|-----------------------------|-------------------------------|-------------------------------|---|
| Age, y (IQR)    | 34 (28–43)                  | 34 (28–43)                    | 35 (30–43)                    | 37 (31–44) | 0.10 |
| Age group, n (%)|                             |                               |                               |             | 0.012 |
| 18–30           | 357 (32.3)                  | 316 (34.3)                    | 30 (25.0)                     | 11 (17.2)  |
| 30–40           | 388 (35.1)                  | 310 (33.7)                    | 51 (42.5)                     | 27 (42.2)  |
| 40–50           | 236 (21.4)                  | 188 (20.4)                    | 27 (22.5)                     | 21 (32.8)  |
| >50             | 124 (11.2)                  | 107 (11.6)                    | 12 (10.0)                     | 5 (7.8)    |
| Male, n (%)     | 792 (71.7)                  | 652 (70.8)                    | 101 (84.2)                    | 39 (60.9)  | 0.001 |
| Route of transmission, n (%) |                   |                               |                               |             |
| MSM             | 411 (37.2)                  | 360 (39.1)                    | 49 (40.8)                     | 2 (3.1)    |
| Heterosexual    | 508 (46.0)                  | 430 (46.7)                    | 63 (52.5)                     | 15 (23.5)  |
| Blood           | 89 (8.0)                    | 47 (5.1)                      | 0 (0.0)                       | 42 (65.6)  |
| Others/unknown  | 97 (8.8)                    | 84 (9.1)                      | 8 (6.7)                       | 5 (7.8)    |
| ALT, IU/L (IQR) | 23 (16–36)                  | 21 (16–33)                    | 29 (20–43)                    | 47 (29–72) |
| AST, IU/L (IQR) | 25 (19.7)                   | 148 (16.1)                    | 31 (25.8)                     | 39 (60.9)  |
| PLT, /C15       | 289 (27.0)                  | 229 (24.8)                    | 33 (27.5)                     | 37 (57.8)  |
| APRI (IQR)      | 0.34 (0.26–0.50)            | 0.32 (0.25–0.45)              | 0.39 (0.29–0.59)              | 0.89 (0.50–1.26) | 0.001 |
| FIB-4 (IQR)     | 1.02 (0.73–1.48)            | 0.97 (0.71–1.36)              | 1.06 (0.76–1.65)              | 1.76 (1.25–2.33) | 0.001 |
| FIB-4 > 1.45, n (%) | 288 (26.1)              | 202 (21.9)                    | 43 (35.8)                     | 43 (67.2)  |
| CD4 cell count, cells/μL (IQR) | 222 (135–303) | 226 (141–306) | 188 (99–277) | 202 (132–299) | 0.009 |
| HIV RNA, log copies/mL (IQR) | 4.65 (4.22–5.11) | 4.65 (4.21–5.10) | 4.70 (4.23–5.16) | 4.55 (3.97–4.93) | 0.46 |
| HBV-active NRTI, n (%) |                     |                               |                               |             | 0.001 |
| TDF + 3TC based | 413 (37.4)                  | 370 (40.2)                    | 38 (31.7)                     | 5 (7.8)    |
| 3TC based (+ AZT or d4T) | 645 (58.4)              | 518 (56.2)                    | 76 (63.3)                     | 51 (79.7)  |
| No              | 47 (4.2)                    | 33 (3.6)                      | 6 (5.0)                       | 8 (12.5)   |
| Third medication |                            |                               |                               |             | 0.001 |
| NVP             | 674 (61.0)                  | 535 (58.1)                    | 80 (66.7)                     | 59 (92.2)  |
| EFV             | 426 (38.5)                  | 382 (41.5)                    | 39 (32.5)                     | 5 (7.8)    |
| PI              | 5 (0.5)                     | 4 (0.4)                       | 1 (0.8)                       | 0 (0.0)    |
| Cohort          |                            |                               |                               |             | <0.001 |
| Outpatient      | 71 (6.4)                    | 65 (7.1)                      | 6 (5.0)                       | 0 (0.0)    |
| 11–5            | 484 (43.8)                  | 389 (42.2)                    | 63 (52.5)                     | 32 (50.0)  |
| 10–5            | 148 (13.4)                  | 107 (11.6)                    | 14 (11.7)                     | 27 (42.2)  |
| 12–5            | 402 (36.4)                  | 360 (39.1)                    | 37 (30.8)                     | 5 (7.8)    |

Continuous variables are reported as medians and interquartile ranges. P values represent the overall differences among the 3 groups. 3TC = lamivudine, ALT = alanine aminotransferase, APRI = AST to platelet ratio index, AST = aspartate transaminase, AZT = zidovudine, d4T = stavudine, EFV = efavirenz, FIB-4 = fibrosis-4, HBV = hepatitis B virus, HCV = hepatitis C virus, HIV = human immunodeficiency virus, IQRs = interquartile ranges, IU = international unit, MSM = men who have sex with men, NRTI = nucleoside reverse transcriptase inhibitors, NVP = nevirapine, PI = protease inhibitor, PLT = platelet, TDF = tenofovir disoproxil fumarate.

Factors Associated With Hepatic Fibrosis at Baseline

Overall, APRI, and FIB-4 scores had an 82.1% agreement, with kappa value 0.53 (P < 0.001). At baseline, approximately 20% of HIV-monoinfected participants had scores considered as moderate-to-significant hepatic fibrosis (19.7% by APRI and 21.9% by FIB-4 scoring systems, Table 1) with higher proportions in both HBV and HCV coinfected participants. Specifically, 36.7% of HIV–HCV coinfected participants had an APRI > 0.5 and 35.8% had an FIB-4 > 1.45. This distribution was the same in HBeAg positive and HBeAg negative participants (data not shown). In HIV–HCV coinfected participants, the prevalence of fibrosis scores above these cut-offs was highest at 76.6% and 67.2% by APRI and FIB-4, respectively.
DISCUSSION

In this study of over 1000 HIV-infected Chinese participants who had liver fibrosis assessed by APRI and FIB-4 before and after cART initiation, 20% of the HIV-monoinfected subjects had scores considered as moderate-to-significant liver fibrosis prior to starting cART. Lower CD4 cell count tended to be associated with an increased risk for higher liver fibrosis scores. Furthermore, this study suggests that both HBV and HCV coinfections are associated with increased risk of hepatic fibrosis in HIV-infected subjects prior to cART. Interestingly, cART use was associated with a significant reduction in fibrosis scores, especially in HIV-monoinfected and HIV–HBV coinfected subjects.

The 20% of HIV-monoinfected subjects who had scores considered as moderate-to-significant hepatic fibrosis is high given that in Chinese subjects with fatty liver, only 4.5% by APRI scoring system (APRI > 0.5) and 9.8% by FIB-4 scoring system (FIB-4 > 1.30) had moderate-to-significant hepatic fibrosis.\(^8\) This high proportion, though, is consistent with previous studies where the prevalence of moderate-to-severe fibrosis ranged from 13.5% to 35.7% in HIV-monoinfected subjects (defined as APRI > 0.5 or FIB-4 > 1.45).\(^8\,10,29\) In addition, our study found that higher CD4 protects against liver disease, an association that was stronger in the APRI rather than the FIB-4 scoring system. Taken together, these data support that HIV infection may be an important factor in the development of hepatic fibrosis, as observed by Price et al.\(^8\) The biological explanation for this finding is unknown, but there are several possibilities. HIV has been shown to infect human hepatic stellate cells, which express C–C chemokine receptor type 5 (CCR5), and are considered as a source of fibrogenesis.\(^5\) Interestingly, maraviroc, a CCR5 antagonist, is associated with regression of hepatic fibrosis.\(^36\) In addition to direct infection of HSCs, HIV-related immune activation may also hasten the progression of liver fibrosis.\(^35\) Other mechanisms, including

---

### TABLE 2. Factors Associated With APRI and FIB-4 Considered as Moderate-to-Significant Hepatic Fibrosis

|                | APRI Score > 0.5 | FIB-4 Score > 1.45 |
|----------------|------------------|-------------------|
|                | Univariate       | Multivariate      | Univariate       | Multivariate      |
|                | OR (95% CI)  P    | OR (95% CI)  P    | OR (95% CI)  P    | OR (95% CI)  P    |
| Coinfection    |                  |                  |                  |                  |
| HIV monoinfection | 1 (1.02–1.50) 0.22 | 1 (0.80–1.07) 0.54 | 1 (1.08–1.50) 1.08 | 1 (0.85–1.36) 0.54 |
| HIV–HBV coinfection | 2.37 (1.58–3.55) 0.001 | 2.15 (1.40–3.30) 0.001 | 1.99 (1.33–2.98) 0.001 | 2.24 (1.40–3.59) 0.001 |
| HIV–HCV coinfection | 13.36 (7.32–24.35) 0.001 | 8.24 (4.13–16.45) 0.001 | 7.29 (4.23–12.56) 0.001 | 6.35 (3.15–12.82) 0.001 |
| Baseline CD4 cell count, cells/\(\mu\)L |                  |                  |                  |                  |
| <200           | 1 (0.56–0.74) 0.21 | 1 (0.49–0.84) 0.22 | 1 (0.49–0.84) 0.22 | 1 (0.57–1.14) 0.22 |
| >200           | 0.56 (0.47–0.89) 0.001 | 0.65 (0.47–0.89) 0.007 | 0.64 (0.47–0.89) 0.001 | 0.80 (0.57–1.14) 0.22 |
| Baseline HIV RNA (per 1 log copies/mL) | 1.13 (0.93–1.37) 0.21 | 1.24 (1.02–1.50) 0.028 | 1.24 (1.02–1.50) 0.028 | 1.08 (0.85–1.36) 0.54 |

Models also adjusted for age, sex, routes of transmission, and cohorts (10th 5-y cohort, 11th 5-y cohort, 12th 5-y cohort, and outpatient clinics). ORs for the factors with \(P\) values < 0.15 were included in the multivariate models.

\(\text{APRI} = \text{AST to platelet ratio index, CI = confidence interval, FIB-4 = fibrosis-4, HBV = hepatitis B virus, HCV = hepatitis C virus, HIV = human immunodeficiency virus, OR = odds ratio.}\)
increased intrahepatic apoptosis, may also contribute to hepatic fibrosis in HIV infection. The association of higher CD4 counts with a reduction in risk of moderate-to-severe fibrosis supports a mechanism of immune activation and less likely a direct effect of HIV infection.

HBV coinfection increased the risk for fibrosis 2-fold and HCV coinfection increased the risk 6- to 8-fold after adjustment for demographic and cohort factors. This increased risk was consistent for both scoring systems and is consistent with prior studies of HIV-infected subjects, which included primarily Caucasian subjects. The other studies also had more subjects with HCV whereas in our cohort, prevalence of HBV coinfection was higher than that of HCV coinfection.

After 48 weeks of cART, the median APRI and FIB-4 scores decreased in the HIV monoinfected and in both HIV-hepatitis groups supporting that cART was associated with improvement in hepatic fibrosis scores early after cART initiation. Despite this, HCV coinfection was still associated with higher fibrosis scores. A cross-sectional study from Europe demonstrated that HIV–HCV coinfection was associated with more severe hepatic fibrosis compared to HCV monoinfection even when HIV infection was controlled by cART.7 In contrast

| TABLE 3. Median Fibrosis Scores Before and Week 24 and 48 After cART |
|-------------|----------------|----------------|----------|----------------|
|            | Baseline     | Week 24       | Week 48  |
|            | Median       | IQR (n)       |         | Median       | IQR (n)       | P        |
|            | APRI         |               |         | FIB-4        |               |         |
| HIV monoinfection | 0.32         | 0.25–0.45 (921) |         | 0.31         | 0.23–0.41 (852) | <0.001  |
| HIV–HBV coinfection | 0.39         | 0.29–0.59 (120) |         | 0.35         | 0.25–0.44 (113) | <0.001  |
| HIV–HCV coinfection | 0.89         | 0.50–1.26 (64)  |         | 0.65         | 0.45–1.75 (51)  | 0.13    |
| HIV monoinfection | 0.97         | 0.71–1.36 (921) |         | 0.84         | 0.61–1.18 (852) | <0.001  |
| HIV–HBV coinfection | 1.06         | 0.76–1.65 (120) |         | 0.91         | 0.65–1.32 (113) | <0.001  |
| HIV–HCV coinfection | 1.76         | 1.25–2.33 (64)  |         | 1.57         | 1.02–3.14 (51)  | 0.71    |

P values were calculated by using Wilcoxon tests for paired samples to compare fibrosis scores at week 24 or 48 with those prior to cART. P < 0.025 was considered statistically significant according to Bonferroni correction.

APRI = AST to platelet ratio index, cART = combination antiretroviral therapy, FIB-4 = fibrosis-4, HBV = hepatitis B virus, HCV = hepatitis C virus, HIV = human immunodeficiency virus, IQRs = interquartile ranges.

| TABLE 4. Factors Associated With Fibrosis Scores at Week 48 |
|-------------|----------------|----------------|----------|----------------|
|            | APRI Scoring System | FIB-4 Scoring System |
|            | Multivariate | Multivariate | Multivariate | Multivariate |
| Coinfection |            |            |            |            |
| HIV monoinfection | 1 | 1 |
| HIV–HBV coinfection | 1.11 (1.01–1.22) | 0.030 | 1.04 (0.97–1.12) | 0.27 |
| HIV–HCV coinfection | 1.97 (1.69–2.30) | <0.001 | 1.24 (1.10–1.40) | <0.001 |
| Baseline HIV RNA (per log copies/mL) | 0.92 (0.88–0.95) | <0.001 | 0.92 (0.88–0.95) | <0.001 |
| CD4 change* | 1 | 1 |
| 1st quartile | 0.96 (0.89–1.03) | 0.23 | 0.94 (0.89–0.99) | 0.028 |
| 2nd–3rd quartile | 0.95 (0.87–1.03) | 0.18 | 0.90 (0.85–0.96) | 0.002 |
| 4th quartile | 1.03 (0.82–1.29) | 0.78 | 1.06 (0.89–1.27) | 0.49 |
| Unknown | 1.03 (0.82–1.29) | 0.78 | 1.06 (0.89–1.27) | 0.49 |
| Viral suppression (<400 copies/mL) | 1 | 1 |
| Yes | 0.95 (0.84–1.07) | 0.40 | 0.94 (0.86–1.04) | 0.25 |
| No | 0.95 (0.80–1.11) | 0.50 | 0.89 (0.78–1.01) | 0.063 |
| Baseline fibrosis score (per 1 point) | 1.40 (1.32–1.49) | <0.001 | 1.58 (1.50–1.67) | <0.001 |

Fold change was calculated by linear regression. Models also adjusted for age, sex, routes of transmission, and cohorts (10th 5-y cohort, 11th 5-y cohort, 12th 5-y cohort, and outpatient clinics). Baseline CD4 cell count was not included because of collinearity with CD4 increase. Fold changes for the factors with P values < 0.15 were included in the multivariate models.

APRI = AST to platelet ratio index, CI = confidence interval, FIB-4 = fibrosis-4, HBV = hepatitis B virus, HCV = hepatitis C virus, HIV = human immunodeficiency virus.

CD4 cell count change was calculated as CD4 cell count at week 48 minus CD4 cell count at baseline and then divided into 4 quartiles, with 1st quartile the smallest change and 4th the largest.
to our findings, a retrospective Canadian study found that APRI scores in HIV-monoinfected subjects remained stable during 14 years of cART while APRI scores in HIV/HCV coinfected subjects increased. However, this Canadian study included primarily Canadian intravenous drug users while our cohort only included Asian nondrug users, which could explain differences in the findings. Another explanation for the difference is that in the Canadian study, the APRI increase was more prominent after 1 year of cART use. Since some of the cART medications are hepatotoxic, the beneficial effect of cART on fibrosis may be outweighed by the direct toxicity of some cART medications in long term, so further follow-up of our cohort is needed to evaluate the effect of longer-term cART on hepatic fibrosis. In fact, drug toxicity could be 1 explanation for the slower decline of median APRI and FIB-4 in the HIV–HCV coinfected participants since they had a higher proportion on drugs that are more hepatotoxic (AZT and d4T, Table 1).

There are several strengths of our study. First, this is the first longitudinal study in Chinese HIV-infected subjects to compare liver fibrosis scores at baseline and during follow-up on cART. Second, we included a large number of subjects and included both HBV and HCV coinfected subjects. Third, we utilized two hepatic fibrosis scoring systems, which demonstrated concordance. Fourth, subjects with alcohol abuse or binge drinking were excluded. An inherent limitation of this study, first of all, is that we used established serum markers as a surrogate for the amount of liver fibrosis, which is less accurate than liver biopsy and has a moderate accuracy for assessing liver fibrosis. However, meta-analyses demonstrate that these markers have moderate accuracy for assessing liver fibrosis. This limitation is outweighed by the large number of subjects included, which would not have been feasible with liver biopsy. Furthermore, our finding that the two different markers produced concordant results also overcomes the limitation of not having liver biopsy data. Second, since HIV infection is associated with reduction in PLT and both scores require PLT, these fibrosis scores may be elevated due to HIV infection rather than hepatic fibrosis; therefore, we did a sensitivity analysis using only AST as a surrogate fibrosis marker, and found similar results. Third, in this study, we cannot distinguish hepatotoxicity flares from changes in fibrosis; however, our findings warrant further study using other noninvasive tests such as transient elastography. Fourth, we were not able to determine the route of transmission for HBV infection, although we presumed that most subjects acquired HBV infection via vertical transmission. Control of HBV infection may have been affected by cART, but we were not able to determine HBV DNA in follow-up in this study.

In conclusion, this study suggests that HIV infection is a risk factor for higher hepatic fibrosis scores in Chinese and these fibrosis scores improve with cART. Furthermore, both HBV and HCV coinfections are associated with higher surrogate fibrosis scores prior to cART, which are also ameliorated with cART. These data provide further support for early initiation of cART in HIV infection.

ACKNOWLEDGMENTS

We thank the study participants for their cooperation. The following clinical institutions or hospitals participated in this study. Northeastern centers included Peking Union Medical College Hospital, Beijing Youan Hospital, Beijing Ditan Hospital, 302 Hospital in Beijing, China Medical University, and Zhengzhou Sixth Hospital. Northwestern center included Tangdu Hospital. Southeastern centers included Guangzhou Eighth People’s Hospital, Shanghai Public Health Clinical Center, Shenzhen Third People’s Hospital, and Fuzhou Infectious Diseases Hospital. Southwestern centers included Chengdu Infectious Diseases Hospital, Changsha First Hospital, Distric CDC in Nanning, Longtan Hospital in Nanning, Nanning Forth People’s Hospital, Yunnan AIDS Care Center, Kunming Third People’s Hospital, and Honghe First People’s Hospital.

REFERENCES

1. Mocroft A, Brettle R, Kirk O, et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS. 2002;16:1663–1671.
2. Louie JK, Hsu LC, Osmond DH, et al. Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994–1998. J Infect Dis. 2002;186:1023–1027.
3. Smith C, Sabin CA, Lundgren JD, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS. 2010;24:1537–1548.
4. Salmon-Ceron D, Lewden C, Morlat P, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol. 2005;42:799–805.
5. Li YJ, Wang HL, Li TS. Hepatitis B virus/human immunodeficiency virus confection: interaction among human immunodeficiency virus infection, chronic hepatitis B virus infection, and host immunity. Chin Med J (Engl). 2012;125:2371–2377.
6. Chen JY, Feeny ER, Chung RT. HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol. 2014;11:362–371.
7. Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology. 2009;49:S138–S145.
8. Price JC, Seaberg EC, Badri S, et al. HIV mono-infection is associated with increased aspartate aminotransferase-to-platelet ratio index, a surrogate marker for hepatic fibrosis. J Infect Dis. 2012;205:1005–1013.
9. de Ledinghen V, Barreiro P, Foucher J, et al. Liver fibrosis scores improve with cART. J Hepatology. 2010;52:1005–1013.
10. Moodie EE, Pant Pai N, Klein MB. Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts. PLoS ONE. 2009;4:e4517.
11. Boyd A, Lasnier E, Molina JM, et al. Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use. Antivir Ther. 2010;15:963–974.
12. Wang H, Xue L, Yan R, et al. Comparison of FIB-4 and APRI in Chinese HBV-infected patients with persistently normal ALT and mildly elevated ALT. J Viral Hepat. 2013;20:e3–e10.
13. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–526.
14. Kim BK, Kim do Y, Park JY, et al. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. Liver Int. 2010;30:546–553.
15. Shin WG, Park SH, Jang MK, et al. Aspartate aminotransferase to platelet ratio index (APRI) can predict liver fibrosis in chronic hepatitis B. Dig Liver Dis. 2008;40:267–274.
16. Nunes D, Fleming C, Offner G, et al. HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. *J Acquir Immune Defic Syndr.* 2005;40:538–544.

17. Cales P, Halfon P, Batisse D, et al. Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection. *J Hepatol.* 2010;53:238–244.

18. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. *Hepatology.* 2006;43:1317–1325.

19. Mendi M, Foca E, Gotti D, et al. Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection. *Clin Infect Dis.* 2011;52:1164–1173.

20. Bambha K, Pierce C, Cox C, et al. Assessing mortality in women with hepatitis C virus and HIV using indirect markers of fibrosis. *AIDS.* 2012;26:599–607.

21. Jain MK, Seremba E, Bhore R, et al. Change in fibrosis score as a predictor of mortality among HIV-infected patients with viral hepatitis. *AIDS Patient Care STDs.* 2012;26:73–80.

22. Berenguer J, Zamora FX, Aldamiz-Echevarria T, et al. Comparison of the prognostic value of liver biopsy and FIB-4 in patients coinfected with the human immunodeficiency virus and hepatitis C virus. *Clin Infect Dis.* 2015;60:950–958.

23. Fuping G, Wei L, Yang H, et al. Impact of hepatitis C virus coinfection on HAART in HIV-infected individuals: multicentric observation cohort. *J Acquir Immune Defic Syndr.* 2010;54:137–142.

24. Wang H, Li Y, Zhang C, et al. Immunological and virological responses to cART in HIV/HBV co-infected patients from a multicenter cohort. *AIDS.* 2012;26:1755–1763.

25. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. *Hepatology.* 2007;46:912–921.

26. Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. *Hepatology.* 2011;53:726–736.

27. Xiao G, Yang J, Yan L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. *Hepatology.* 2015;61:292–302.

28. Wong VW, Chu WC, Wong GL, et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. *Gut.* 2012;61:409–415.

29. Blackard JT, Welge JA, Taylor LE, et al. HIV mono-infection is associated with FIB-4: a noninvasive index of liver fibrosis—in women. *Clin Infect Dis.* 2011;52:674–680.

30. Gonzalez EO, Boix V, Deltoro MG, et al. The effects of Maraviroc on liver fibrosis in HIV/HCV co-infected patients. *J Int AIDS Soc.* 2014;17:19643.

31. Marchetti G, Cozzi-Lepri A, Tincati C, et al. Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation Study. *BMC Infect Dis.* 2014;14:79.

32. Iser DM, Avihingsanon A, Wisedopas N, et al. Increased intrahepatic apoptosis but reduced immune activation in HIV-HBV co-infected patients with advanced immunosuppression. *AIDS.* 2011;25:197–205.

33. Blanco F, Barreiro P, Ryan P, et al. Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance. *J Viral Hepat.* 2011;18:11–16.

34. Shah AG, Smith PG, Sterling RK. Comparison of FIB-4 and APRI in HIV-HCV coinfected patients with normal and elevated ALT. *Dig Dis Sci.* 2011;56:3038–3044.

35. Fan HW, Guo FP, Li YJ, et al. Prevalence of thrombocytopenia among Chinese adult antiretroviral-naive HIV-positive patients. *Chin Med J (Engl).* 2015;128:459–464.